Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA.~2. Infants who are entering their first full RSV season at the time of screening.~Key Exclusion Criteria:~1. Meets American Academy of Pediatrics (AAP) or other local criteria to receive commercial palivizumab.~2. Any fever (\>= 100.4°F \[\>= 38.0°C\], regardless of route) or lower respiratory illness within 7 days prior to randomization.~3. Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization.~4. Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection.~5. Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 365 Days
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
- MEDI8897 50 mg (Type: EXPERIMENTAL): Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).